Abstract 112P
Background
Colorectal liver metastasis (CLM) is classified as Resectable, Unresectable, and Borderline resectable (BR) based on Technical and Oncological categories, with recommended treatments tailored to each classification. However, there is currently no appropriate classification for instances of liver recurrence in CLM (r-CLM).
Methods
This study evaluated patients with CLM who underwent initial liver resection between 2006 and 2020 and subsequently experienced liver recurrences. We investigated the long-term outcomes and prognostic factors related to r-CLM.
Results
Out of 949 cases of initial liver resection, 650 cases experienced recurrence, and among them, 392 cases were identified as r-CLM. Early recurrence within one year (er-CLM) exhibited significantly poorer overall survival (OS) compared to instances of r-CLM recurring after one year (p < 0.0001). Nonetheless, even within the er-CLM group, resected er-CLM showed notably improved prognosis in comparison to the non-resected group (5-year OS: 48.1% vs. 0%, p < 0.0001). Multivariate analysis of er-CLM identified independent prognostic factors as the number of recurrent tumors (≥ 4) (HR, 1.95; 95% CI, 1.24-3.07; p = 0.004), tumor size (≥ 5cm) (HR, 3.77; 95% CI, 1.46-9.76; p = 0.006), and presence of extrahepatic diseases (HR, 1.71; 95% CI, 1.09-2.71; p = 0.021). Stratifying these factors for recurrence-Resectable and recurrence-BR cases resulted in a significant difference in prognosis between the two groups (59.5% vs. 26.5%, p < 0.001).
Conclusions
Even in cases of early recurrence within one year, repeat liver resection contributes to extending prognosis. Regardless of the background at the initial liver resection, the number of r-CLM, tumor size, and presence of extrahepatic diseases were identified independent prognostic factors. Tailoring appropriate treatment based on the characteristics of recurrent tumors holds the potential to enhance the prognosis for r-CLM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract